Posts

Lakefront sells cell therapy pipeline to Armed Cell

on
Lakefront Biotherapeutics, formerly Galapagos, sold its early-stage cell therapy pipeline to Belgian startup Armed Cell Therapeutics. The deal includes €8 million upfront, up to $230 million in milestone payments, and a low-single-digit royalty for Lakefront. The transferred portfolio includes preclinical, engineered CAR-T programs intended to improve potency and persistence and address treatment resistance in blood cancers and solid tumors. Armed Cell will develop the programs independently. Armed Cell was formed by biotech executives including former Galapagos CEO Paul Stoffels. The sale follows Lakefront’s decision to wind down its cell therapy activities. Sources: Rebranded Galapagos finally finds buyer for cell therapies Stoffels strikes up new biotech in return to Galapagos cell therapy mission Galapagos abandons cell therapy, putting 365 jobs at risk Belgian startup revives Galapagos CAR-T research Cell & Gene Therapy Fierce Biotech Lakefront Announces ...

NorthStar partners with Quarkmed to support Ac-225 drug filings in China

on

Iambic raises $150 million in IPO to advance cancer drug pipeline

on

AstraZeneca and insitro partner on AI-led liver and heart drug discovery

on

Vanda puts social-anxiety drug program on hold after Phase 3 setback

on

Verastem’s early KRAS drug results draw bold CEO claim

on

Rakovina secures exclusivity for AI-optimized KT-5000 profile

on

Shared barriers keep Leqembi and Kisunla uptake challenging

on

Verastem’s VS-7375 posts early pancreatic cancer responses, setting up a KRAS rivalry

on

FDA proposes a more consistent—but tailored—approach to rare-disease drugs

on

OMass raises $310 million to advance experimental adrenal-disorder drug

on

DaltonTx receives Gates Foundation grant for AI-powered TB drug discovery

on

Biomea’s early oral GLP-1 data leave investors waiting for stronger evidence

on